After finishing at $12.60 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $12.29, down -2.46%. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 4188419 shares were traded.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 2.78 whereas as Long-Term Debt/Eq ratio is at 2.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $20 from $15 previously.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 ’24 when MCGLYNN MARGARET G sold 7,500 shares for $13.40 per share. The transaction valued at 100,500 led to the insider holds 59,289 shares of the business.
MCGLYNN MARGARET G sold 7,500 shares of FOLD for $99,675 on Mar 04 ’24. The Director now owns 59,289 shares after completing the transaction at $13.29 per share. On Mar 01 ’24, another insider, Crowley John F, who serves as the Executive Chairman of the company, sold 29,181 shares for $13.35 each. As a result, the insider received 389,543 and left with 573,478 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3.63B and an Enterprise Value of 3.79B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.09 while its Price-to-Book (P/B) ratio in mrq is 22.53. Its current Enterprise Value per Revenue stands at 9.49 whereas that against EBITDA is -41.15.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.70. The 50-Day Moving Average of the stock is 13.25, while the 200-Day Moving Average is calculated to be 12.38.
Shares Statistics:
The stock has traded on average 3.27M shares per day over the past 3-months and 3.71M shares per day over the last 10 days, according to various share statistics. A total of 293.59M shares are outstanding, with a floating share count of 286.50M. Insiders hold about 3.01% of the company’s shares, while institutions hold 106.62% stake in the company. Shares short for FOLD as of Feb 15, 2024 were 26.78M with a Short Ratio of 8.20, compared to 25.06M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.12% and a Short% of Float of 9.16%.
Earnings Estimates
Its stock is currently analyzed by 9 different market analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.07, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.01 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.18 and -$0.09 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.4, with 9 analysts recommending between $0.62 and $0.17.
Revenue Estimates
9 analysts predict $113.07M in revenue for the current quarter. It ranges from a high estimate of $119M to a low estimate of $109.2M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $83.08M, an estimated increase of 36.10% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $126.3M, an increase of 33.60% less than the figure of $36.10% in the same quarter last year. There is a high estimate of $129.46M for the next quarter, whereas the lowest estimate is $123.34M.
A total of 10 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $548.49M, while the lowest revenue estimate was $511.09M, resulting in an average revenue estimate of $532.61M. In the same quarter a year ago, actual revenue was $399.36M, up 33.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $684.86M in the next fiscal year. The high estimate is $798.27M and the low estimate is $618.98M. The average revenue growth estimate for next year is up 28.60% from the average revenue estimate for this year.
